Company also announces new Chief Scientific Officer

  • AC Immune names Christopher Roberts permanent CFO
  • Madiha Derouazi appointed as Chief Scientific Officer
  • Marie Kosco-Vilbois to retire but remain as a consultant
  • Roberts has been with AC Immune since 2019

AC Immune, the clinical-stage biopharmaceutical company based in Lausanne, Switzerland, has announced that Christopher Roberts has been named as the permanent Chief Financial Officer. Roberts, who joined AC Immune in 2019, had been serving as the interim CFO since early 2022. In addition, the company has appointed Madiha Derouazi as the new Chief Scientific Officer, effective January 1. Derouazi, previously the CEO of Speransa Therapeutics, will be taking over from Marie Kosco-Vilbois, who is retiring but will continue to assist as a consultant during the transition period.

Public Companies: AC Immune (N/A)
Private Companies: Speransa Therapeutics
Key People: Christopher Roberts (Chief Financial Officer), Madiha Derouazi (Chief Scientific Officer), Marie Kosco-Vilbois (Consultant), Joerg Hornstein (Former Chief Financial Officer)

Factuality Level: 8
Justification: The article provides factual information about the appointments of Christopher Roberts as CFO and Madiha Derouazi as CSO at AC Immune. It also mentions the previous positions of the individuals and the retirement of Marie Kosco-Vilbois. The information seems to be straightforward and does not contain any obvious bias or opinion.

Noise Level: 3
Justification: The article provides straightforward information about the appointment of a new CFO and CSO at AC Immune. There is no irrelevant or misleading information, and it stays on topic. However, it lacks scientific rigor, intellectual honesty, and actionable insights. It is a simple announcement without any analysis or evidence to support the claims.

Financial Relevance: Yes
Financial Markets Impacted: AC Immune

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to the appointment of a new chief financial officer and chief scientific officer at AC Immune, a clinical-stage biopharmaceutical company. While this news is relevant to the financial sector, it does not describe any extreme events or their impacts.

Reported publicly: www.marketwatch.com